Celltrion Healthcare said Thursday that Truxima (Ingredient: rituximab-abbs), a monoclonal antibody (mAb) biosimilar for treating adult patients with non-Hodgkin’s lymphoma, has acquired 35 percent of Europe’s rituximab market in the third quarter of last year.
In particular, European physicians' confidence in Truxima has increased with the 36 percent market share in the five major countries, which account for 70 percent of the European rituximab market, including 66 percent in the U.K., 42 percent in France and 31 percent in Italy.
Truxima’s prescription expansion rate is three to four times faster, given that Remsima (ingredient name: Infliximab), a biosimilar for the treatment for autoimmune diseases, reached 11 percent market share in Europe in the second year of its launch.
As Truxima's market expansion is successful, the company expects that it will have a positive impact on launching the product in the U.S. market.
Celltrion also forecasts that it will be able to expand prescription in the U.S. as Truxima's real-world data (RWD) in Europe continues to accumulate in addition to the U.S. administration’s biosimilar-friendly policies and the drug’s price competitiveness.
“All three major biosimilars of Celltrion are recognized in the medically advanced Europe and are steadily expanding their markets,” a company official said. “We will do our best to succeed in the U.S. market for Truxima based on our success in Europe."
<© Korea Biomedical Review, All rights reserved.>